Last updated on February 2018

Safety Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alzheimer's Disease
  • Age: Between 19 - 50 Years
  • Gender: Male

Inclusion Criteria:

  • Men aged 19 to 50 years
  • Body weight 55 to 90 kg and BMI 18.0 to 27.0
  • Voluntarily signed the informed consent form
  • Eligible according to the screening test results
  • Available to follow up after drop-out

Exclusion Criteria:

  • Clinically significant disorders or a medical history of hepatic, renal, neurological, respiratory, endocrine, hemato-oncologic, cardiovascular, urological and psychiatric diseases
  • Hypersensitivity to donepezil, piperidine derivatives and other drugs
  • SBP <100 mmHg or >150 mmHg, or DBP <60 mmHg or >100 mmHg
  • Skin and muscle disorders or history of surgery at the injection site
  • AST or ALT >1.5xULN; QT/QTcB interval >450 ms
  • History or positive result of drug abuse
  • Prescribed drugs or herbal medicines within 2 weeks, over-the-counter drugs or vitamins within 1 week
  • Participated in other clinical trials within 3 months
  • Donated whole blood within 2 months or apheresis within 1 month, or transfusion within 1 month
  • Alcohol consumption >21 units/week
  • Smoked >10 cigarettes/day within 3 months
  • Caffeine-containing foods
  • Not eligible due to other reasons at the investigator's discretion

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.